Rubella vaccine--how 'reactogenic' is it?
Girls (231) aged 11-13 years were allocated at random to receive one of two RA27/3 rubella vaccines. A high incidence of minor and self-limiting side-effects were found by intensive follow-up. No difference in reactogenicity could be found between vaccines from the Institut Merieux and Wellcome. This study confirms the highly acceptable risk/benefit ratio of vaccination against rubella in the U.K.
D000293:Adolescent; D002648:Child; D003875:Drug Eruptions / Q000209:etiology; D005260:Female; D006801:Humans; D010146:Pain / Q000209:etiology; D011897:Random Allocation; D012411:Rubella Vaccine / Q000009:adverse effects*
D012411:Rubella Vaccine